Skin tight: Debt hits derm, quiz Valeant 'core' values in $2B-plus assets sell-off
By Randy Osborne
Tuesday, January 10, 2017
During a third-quarter earnings conference call in November with investors, when asked about divestitures that could help the company chip away at major debt and focus on the main business, Valeant Pharmaceuticals International Inc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.